Big Pharma players are likely to be most successful at turning out generic versions of biotech drugs, or biosimilars, because major drugmakers have the necessary marketing muscle and development expertise, Reuters reports. Report
Big Pharma players are likely to be most successful at turning out generic versions of biotech drugs, or biosimilars, because major drugmakers have the necessary marketing muscle and development expertise, Reuters reports. Report